Synagis® has been shown to reduce the rate of RSV-related hospitalizations in premature infants (≤35 weeks GA) by more than half 1 Significant reduction in RSV-related hospitalization rates with Synagis vs. placebo1-3 - Hospitalization - Document - PDFSEARCH.IO

First Page	Meta Content
	Synagis® has been shown to reduce the rate of RSV-related hospitalizations in premature infants (≤35 weeks GA) by more than half 1 Significant reduction in RSV-related hospitalization rates with Synagis vs. placebo1-3 Add to Reading List Document Date: 2014-04-30 14:26:38 Open Document File Size: 83,75 KB Share Result on Facebook City Gaithersburg / / Company MedImmune / / Product Synagis / / ProvinceOrState Georgia / Maryland / / SocialTag Mononegavirales Human respiratory syncytial virus Palivizumab Biology Health MedImmune Placebo AstraZeneca Medicine Viral diseases

Synagis® has been shown to reduce the rate of RSV-related hospitalizations in premature infants (≤35 weeks GA) by more than half 1 Significant reduction in RSV-related hospitalization rates with Synagis vs. placebo1-3Add to Reading List